JP2020534351A5 - - Google Patents

Download PDF

Info

Publication number
JP2020534351A5
JP2020534351A5 JP2020534793A JP2020534793A JP2020534351A5 JP 2020534351 A5 JP2020534351 A5 JP 2020534351A5 JP 2020534793 A JP2020534793 A JP 2020534793A JP 2020534793 A JP2020534793 A JP 2020534793A JP 2020534351 A5 JP2020534351 A5 JP 2020534351A5
Authority
JP
Japan
Prior art keywords
seq
cdr
tm4sf1
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020534793A
Other languages
English (en)
Japanese (ja)
Other versions
JP7241080B2 (ja
JP2020534351A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/048402 external-priority patent/WO2019046338A1/en
Publication of JP2020534351A publication Critical patent/JP2020534351A/ja
Publication of JP2020534351A5 publication Critical patent/JP2020534351A5/ja
Priority to JP2023033463A priority Critical patent/JP2023071888A/ja
Application granted granted Critical
Publication of JP7241080B2 publication Critical patent/JP7241080B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020534793A 2017-08-28 2018-08-28 抗tm4sf1抗体およびそれを使用する方法 Active JP7241080B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023033463A JP2023071888A (ja) 2017-08-28 2023-03-06 抗tm4sf1抗体およびそれを使用する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762550994P 2017-08-28 2017-08-28
US62/550,994 2017-08-28
PCT/US2018/048402 WO2019046338A1 (en) 2017-08-28 2018-08-28 ANTI-TM4SF1 ANTIBODIES AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023033463A Division JP2023071888A (ja) 2017-08-28 2023-03-06 抗tm4sf1抗体およびそれを使用する方法

Publications (3)

Publication Number Publication Date
JP2020534351A JP2020534351A (ja) 2020-11-26
JP2020534351A5 true JP2020534351A5 (cg-RX-API-DMAC7.html) 2021-10-07
JP7241080B2 JP7241080B2 (ja) 2023-03-16

Family

ID=65526015

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020534793A Active JP7241080B2 (ja) 2017-08-28 2018-08-28 抗tm4sf1抗体およびそれを使用する方法
JP2023033463A Pending JP2023071888A (ja) 2017-08-28 2023-03-06 抗tm4sf1抗体およびそれを使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023033463A Pending JP2023071888A (ja) 2017-08-28 2023-03-06 抗tm4sf1抗体およびそれを使用する方法

Country Status (8)

Country Link
US (3) US11208495B2 (cg-RX-API-DMAC7.html)
EP (1) EP3675906A4 (cg-RX-API-DMAC7.html)
JP (2) JP7241080B2 (cg-RX-API-DMAC7.html)
CN (1) CN111565750B (cg-RX-API-DMAC7.html)
AU (1) AU2018323470B2 (cg-RX-API-DMAC7.html)
CA (1) CA3074111A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020002241A (cg-RX-API-DMAC7.html)
WO (1) WO2019046338A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3383482B1 (en) 2015-11-24 2023-01-04 Massachusetts Institute of Technology Systems for preventing, mitigating, and/or treating dementia
CA3044440A1 (en) 2016-11-17 2018-05-24 Cognito Therapeutics, Inc. Methods and systems for neural stimulation via visual stimulation
MX2020002241A (es) * 2017-08-28 2020-09-03 Angiex Inc Anticuerpos anti-tm4sf y métodos de uso de los mismos.
ES3058718T3 (en) 2017-10-10 2026-03-12 Massachusetts Inst Technology Systems for preventing, mitigating, and/or treating dementia
US10960225B2 (en) 2017-10-10 2021-03-30 Massachusetts Institute Of Technology Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function
EP3807644A4 (en) * 2018-06-12 2022-07-06 Angiex, Inc. ANTIBODY-OLIGONUCLEOTIDE CONJUGATES
MX2021010254A (es) 2019-02-27 2021-09-21 Angiex Inc Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos.
CN110734494B (zh) * 2019-10-30 2021-04-30 上海市第一人民医院 抗tspan8单克隆抗体及其用途
MX2022011958A (es) * 2020-03-27 2023-01-11 Angiex Inc Conjugados de anticuerpo degradador y métodos de uso de los mismos.
WO2021222783A1 (en) * 2020-05-01 2021-11-04 Angiex, Inc. Anti-tm4sf1 antibody drug conjugates and methods of using same
EP4188449A4 (en) * 2020-07-31 2025-12-17 Angiex Inc ANTI-TM4SF1 ANTIBODY AGENT CONJUGATES WITH CRISPABLE LINKERS AND METHOD FOR USE THEREMISH
WO2022046941A1 (en) * 2020-08-26 2022-03-03 Angiex, Inc. Antimitotic tetrapeptide-antibody conjugates and methods of using same
AU2022242927A1 (en) * 2021-03-26 2023-10-05 Angiex, Inc. Combinations comprising anti-tm4sf1 antibodies and immunotherapeutic agents and methods of using the same
JP2024511479A (ja) * 2021-03-26 2024-03-13 アンジーエックス・インコーポレーテッド メイタンシン抗体コンジュゲートおよびそれを使用する方法
JPWO2022255401A1 (cg-RX-API-DMAC7.html) * 2021-06-03 2022-12-08
EP4349358A4 (en) * 2021-06-03 2025-05-28 Medpacto, Inc. TM4SF19 INHIBITOR AND ITS USES

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20040214872A1 (en) 2002-09-26 2004-10-28 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
EP2385114A4 (en) * 2008-12-25 2012-08-08 Univ Tokyo CANCER TREATMENT DIAGNOSIS WITH ANTI-TM4SF20 ANTIBODY
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
EP2699256B1 (en) 2011-04-21 2017-09-27 The Regents of the University of Colorado, a body corporate Compositions and methods for the treatment of neuromyelitis optica
CN102590531A (zh) * 2012-03-24 2012-07-18 广西壮族自治区肿瘤防治研究所 卵巢癌相关抗原自身抗体谱液相芯片检测试剂盒及其制备方法
WO2015054427A1 (en) * 2013-10-10 2015-04-16 Beth Israel Deaconess Medical Center, Inc. Tm4sf1 binding proteins and methods of using same
PE20160654A1 (es) 2013-11-22 2016-07-15 Pharmakea Inc Compuestos de inhibidor de autotaxina
LT3148579T (lt) 2014-05-28 2021-05-25 Agenus Inc. Anti-gitr antikūnai ir jų panaudojimo būdai
MX2020002241A (es) * 2017-08-28 2020-09-03 Angiex Inc Anticuerpos anti-tm4sf y métodos de uso de los mismos.

Similar Documents

Publication Publication Date Title
US11136413B2 (en) PDL-1 antibody, pharmaceutical composition thereof, and uses thereof
JP2023504003A5 (cg-RX-API-DMAC7.html)
IL293241A (en) Bispecific antibody, anti-1-pd, anti-vegfa, pharmaceutical preparation containing it and its use
JP2020520665A5 (cg-RX-API-DMAC7.html)
JP2025506318A (ja) 抗tigit抗体と抗pd-1-抗vegfa二重特異性抗体を含有する医薬組成物及び使用
AU2019356806B2 (en) Antibody constructs binding 4-1BB and tumor-associated antigens and uses thereof
JP2016514676A (ja) 四価二重特異性抗体
JP2023522730A5 (cg-RX-API-DMAC7.html)
JP2022540620A5 (cg-RX-API-DMAC7.html)
JP2024540148A5 (cg-RX-API-DMAC7.html)
KR20210027254A (ko) Tim-3에 대한 항체 및 그의 용도
JP2024532372A5 (cg-RX-API-DMAC7.html)
US20230340119A1 (en) Composition of triax antibodies and method of making and using thereof
WO2019242619A1 (zh) 全人源的抗lag-3抗体及其应用
CA3146977A1 (en) Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof
JP2025517737A5 (cg-RX-API-DMAC7.html)
CN114269784A (zh) 具有选择性可切割接头的双特异性结合构建体
JP2023532852A5 (cg-RX-API-DMAC7.html)
CN116783217A (zh) 具有多个结合结构域的免疫球蛋白构建体
JP7811028B2 (ja) ヒトcxcl16抗体およびその使用
TW202506193A (zh) Trop2結合劑及其結合物
JP2025521246A (ja) インテグリンベータ-2を標的とする抗体
CN119698436A (zh) 人cd33抗体和糖皮质激素缀合物
US20260109769A1 (en) Pd-1 bnding proteins, vegf and pd-1 bispecific binding proteins, compositions, and methods of use
WO2024141049A1 (zh) 抗ox40抗体及其应用